​

Inhibrx Biosciences (INBX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

INBX Stock Forecast

Inhibrx Biosciences (INBX) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $325.00, with a high of $325.00 and a low of $325.00. This represents a 263.25% increase from the last price of $89.47.

- $70 $140 $210 $280 $350 High: $325 Avg: $325 Low: $325 Last Closed Price: $89.47

INBX Stock Rating

Inhibrx Biosciences stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (60.00%), 2 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 2 3 Strong Sell Sell Hold Buy Strong Buy

INBX Price Target Upside V Benchmarks

TypeNameUpside
StockInhibrx Biosciences263.25%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts111
Avg Price Target$325.00$325.00$325.00
Last Closing Price$89.47$89.47$89.47
Upside/Downside263.25%263.25%263.25%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26-21--3
May, 26-11--2
Apr, 26--1--1
Mar, 26--1--1
Feb, 26--1--1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 15, 2026Stifel Nicolaus$325.00$108.13200.56%263.25%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 17, 2025CitigroupMarket PerformMarket Performhold
Nov 19, 2025CitigroupMarket PerformMarket Performhold
Jul 23, 2024JMP SecuritiesOutperformMarket Performinitialise
Aug 23, 2023JMP SecuritiesOutperformOutperformhold

Financial Forecast

EPS Forecast

$-50 $-10 $30 $70 $110 $150 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.15$-3.62$-5.12$116.58$-9.04---
Avg Forecast$-2.16$-3.36$-4.39$-5.87$-6.17$-5.04$-2.43$-3.40
High Forecast$-2.16$-3.36$-4.29$-5.87$-6.17$-5.04$-2.43$-3.40
Low Forecast$-2.16$-3.36$-4.49$-5.87$-6.17$-5.04$-2.43$-3.40
Surprise %-0.46%7.74%16.63%-2086.03%46.52%---

Revenue Forecast

$0 $70M $140M $210M $280M $350M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.13M$2.19M$1.80M$200.00K$1.30M---
Avg Forecast$6.10M$2.60M$250.00K$250.00K$2.00M$121.96M$337.85M$346.75M
High Forecast$6.10M$2.60M$250.00K$250.00K$2.00M$121.96M$337.85M$346.75M
Low Forecast$6.10M$2.60M$250.00K$250.00K$2.00M$121.96M$337.85M$346.75M
Surprise %16.80%-15.69%620.00%-20.00%-34.84%---

Net Income Forecast

$-500M $0 $500M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-81.77M$-145.23M$-241.36M$1.69B$-140.06M---
Avg Forecast$-84.59M$-97.33M$-271.15M$-276.42M$-290.79M$-237.54M$-114.53M$-160.24M
High Forecast$-67.67M$-77.87M$-216.92M$-276.42M$-290.79M$-237.54M$-114.53M$-160.24M
Low Forecast$-101.50M$-116.80M$-325.39M$-276.42M$-290.79M$-237.54M$-114.53M$-160.24M
Surprise %-3.33%49.21%-10.99%-710.52%-51.84%---

INBX Forecast FAQ

Is Inhibrx Biosciences stock a buy?

Inhibrx Biosciences stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Inhibrx Biosciences is a favorable investment for most analysts.

What is Inhibrx Biosciences's price target?

Inhibrx Biosciences's price target, set by 5 Wall Street analysts, averages $325 over the next 12 months. The price target range spans from $325 at the low end to $325 at the high end, suggesting a potential 263.25% change from the previous closing price of $89.47.

How does Inhibrx Biosciences stock forecast compare to its benchmarks?

Inhibrx Biosciences's stock forecast shows a 263.25% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Inhibrx Biosciences over the past three months?

  • June 2026: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Inhibrx Biosciences’s EPS forecast?

Inhibrx Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $-5.04, marking a -44.25% decrease from the reported $-9.04 in 2025. Estimates for the following years are $-2.43 in 2027, and $-3.4 in 2028.

What is Inhibrx Biosciences’s revenue forecast?

Inhibrx Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $121.96M, reflecting a 9281.38% increase from the reported $1.3M in 2025. The forecast for 2027 is $337.85M, and $346.76M for 2028.

What is Inhibrx Biosciences’s net income forecast?

Inhibrx Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $-238M, representing an 69.60% increase from the reported $-140M in 2025. Projections indicate $-115M in 2027, and $-160M in 2028.